Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Status changed from active, no longer recruiting to discontinued due to lack of drug availability, according to results presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research.